Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Avadomide · CC-122, BMS-986381

Small molecule (Molecular glue degrader) · Degrader of cereblon (CRBN) · developed by BRISTOL MYERS SQUIBB

Phase 1 Most advanced trial
BMY Developer
1 Registered trials

What is Avadomide?

Avadomide is an orally administered small molecule that binds cereblon and redirects the Cullin-4 RING E3 ubiquitin ligase to degrade the transcription factors Aiolos and Ikaros. It is being studied in non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CC-122, BMS-986381
Drug type
Small molecule (Molecular glue degrader)
Targets
cereblon (CRBN), Aiolos (IKZF3) (binding partner it blocks), Ikaros (IKZF1) (binding partner it blocks)
Mechanism
Degrader of cereblon (CRBN)
Pathways
Cullin-4 RING E3 ubiquitin ligase degradation, interferon-stimulated gene derepression, IL-2 production and T-cell costimulation, NK cell activation
Therapy area
Oncology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
28DZS29F59

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05688475 Phase 1 Non-Hodgkin Lymphoma Active not recruiting BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Hodgkin Lymphoma

Other drugs acting on CRBN

More from BRISTOL MYERS SQUIBB

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Avadomide

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.